Dapagliflozin (Forxiga®) is indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as:
When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.
Add-on combination therapy
In combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
|10th October 2012||22nd October 2012||Full pharmacoeconomic Evaluation Recommended|
|01/08/2013||31/12/2013||Reimbursement not recommended at this time.|
The HSE has approved reimbursement following confidential price negotiations.